Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Cumberland Pharmaceuticals Inc. (CPI) is developing ifetroban for treatment of hepatorenal
syndrome (HRS) and proposes to conduct a study in hospitalized adult patients with HRS to
assess the safety and pharmacokinetics of escalating doses of ifetroban.
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to
placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of
Investigational Medicinal Product (IMP) (Study Day 1 or 2) prior to initiation of the
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study
is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous
systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Not yet recruiting
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for
the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that
involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other
nonsteroidal anti-inflammatory drugs.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.